FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Refuses to Review Genzyme sBLA for Lemtrada

[ Price : $8.95]

FDA slaps Genzyme with a refuse-to-file letter on a supplemental BLA for Lemtrada (alemtuzumab) as a treatment for relapsing multi...

Gilead Sciences HIV Drug Stribild Approved

[ Price : $8.95]

FDA approves a Gilead Sciences NDA for Stribild, a once-a-day combination pill to treat HIV-1 infection in adults.

FDA Lifts Clinical Hold on Wet AMD Drug

[ Price : $8.95]

FDA lifts a clinical hold against Lpath and its iSonep, an anti-S1P monoclonal antibody that is being developed as a potential tre...

Guidance on Self-Identification of Generic Drug Facilities

[ Price : $8.95]

FDA releases a draft guidance on the self-identification requirement under generic drug user fee act.

FDA Approves Mallinckrodt Supplement for Exalgo

[ Price : $8.95]

FDA approves a Mallinckrodt supplemental NDA for a 32 mg tablet strength of Exalgo (hydromorphone HCI) extended-release tablets fo...

FDA Places Hold on Second Idenix Compound

[ Price : $8.95]

FDA places a clinical hold on Idenix Pharmaceuticals investigational nucleotide polymerase inhibitor IDX19368 that is being develo...

Goodbye! FDA Shuts the Door (Again) on Our Village Square

[ Price : $8.95]

Closing a 38-year interactive connection with rank-and-file FDA employees, FDA Webview editor Jim Dickinson says goodbye to FDA em...

Are FDA Reviewers Really Protecting Confidential Information?

[ Price : $8.95]

A recent qui tam lawsuit by FDA reviewers and an insider trading case prompt a prominent lawyer to raise questions about FDAs abil...

FDA Approves Excor Pediatric Heart Failure System

[ Price : $8.95]

FDA approves a Berlin Heart humanitarian device exemption for the Excor Pediatric System, a device intended to support the weakene...

Product Approval Summaries

[ Price : $8.95]

FDA Review posts product approval summaries for the week ending 12/16.